EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy
In EGFR‑mutant transformed small cell lung cancer, intratumoral heterogeneity exists that can be therapeutically targeted with a combination of MEK inhibitors.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- Extensive-stage Small Cell Lung Cancer - Gallipoli Medical Research
- Treatment of Small‑Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline
- Does maintenance/consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC)? A metaanalysis of the published controlled trials.
- Cancer's protective shield: Blocking a signaling pathway could make small cell lung tumors visible to T cells
- Radiogenomics of clear‑cell renal cell carcinoma: Associations between CT imaging features and mutations